News und Analysen
![The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a biotech company with a keen focus on developing therapies to treat ultra-rare diseases, moved steadily higher by 13% during the month of July
![Here's Why Coherus Biosciences Rose as Much as 22.2% Today](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
![Why Align Technology's Shares Soared 11.4% In July](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
![What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
![Here's Why Array BioPharma Inc. Fell 13.7% in July](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
![Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
![Here's Why Mazor Robotics Ltd. Gained 20% in July](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Here's Why Mazor Robotics Ltd. Gained 20% in July
Shares of robot-assisted surgery start-up Mazor Robotics Ltd. (NASDAQ: MZOR) gained 20% in July, according to data from S&P Global Market Intelligence. The market boosted the stock in response to news
![Better Buy: Intuitive Surgical, Inc. vs. Medtronic plc](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Better Buy: Intuitive Surgical, Inc. vs. Medtronic plc
Investing in medical device companies can be ridiculously profitable.Since their respective IPOs, shares of Intuitive Surgical (NASDAQ: ISRG) -- maker of the daVinci robotic surgical system -- and
![The Top Stock You Should Consider for Your IRA](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
The Top Stock You Should Consider for Your IRA
If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA, you won't have to pay
![10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year
If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation
![Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:
![Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a staple in the portfolios of conservative long-term investors and seniors alike.For decades, J&J, as the company is more commonly known, has
![Celgene vs. Gilead Sciences: Who Reported Better Earnings?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very
![Quintiles IMS Holdings Continues to Execute](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quintiles IMS Holdings Continues to Execute
Quintiles IMS Holdings (NYSE: Q), a leading service provider to the healthcare and life sciences industries, reported its second-quarter results on Aug. 3. While year-over-year comparisons continue to
![Exelixis, Inc. Grows Revenue, Eyes Treating More Patients](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.MetricQ2 2017Continue
![Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?
Illumina (NASDAQ: ILMN) and Intuitive Surgical (NASDAQ: ISRG) recently reported second-quarter earnings that were better than industry watchers' forecasts. These two game-changing healthcare companies
![AstraZeneca plc: Buy the Dip?](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
![Why Vertex Pharmaceuticals Skyrocketed 17.8% in July](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
![3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
Any way you look at, Exelixis (NASDAQ: EXEL) just reported an impressive second-quarter performance. The biotech posted its second quarter of profitability, with earnings topping Wall Street
![Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late
![ResMed Tops Expectations but Falls Anyway](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
ResMed Tops Expectations but Falls Anyway
Medical-device maker ResMed (NYSE: RMD) reported its fiscal fourth-quarter results after the market closed on Tuesday, Aug. 1. The continuous positive airway pressure (CPAP) pioneer reported modest
![10 Reasons Illumina's Momentum Is Just Cranking Up](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings
![IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
IDEXX Laboratories (NASDAQ: IDXX) reported solid revenue growth with operating income and earnings growing even faster allowing the animal diagnostic company to raise 2017 guidance.But investors
![Illumina Soars After Crushing Expectations for Q2](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3%
![A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus